REPL
Replimune Group Inc
NASDAQ: REPL · HEALTHCARE · BIOTECHNOLOGY
$2.38
-7.39% today
Updated 2026-04-29
Market cap
$212.21M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.44
Dividend yield
—
52W range
$2 – $13
Volume
5.4M
Replimune Group Inc (REPL) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-7.08M | $-16.01M | $-25.38M | $-60.55M | $-61.39M | $-82.18M | $-128.05M | $-185.47M | $-192.25M |
| Capital expenditures | $238000.00 | $136000.00 | $2.60M | $6.54M | $2.39M | $2.34M | $2.27M | $5.66M | $6.69M |
| Depreciation | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $208000.00 | $812000.00 | $2.73M | $7.74M | $11.79M | $24.25M | $28.13M | $34.13M | $35.04M |
| Free cash flow | $-7.32M | $-16.15M | $-27.98M | $-67.09M | $-63.78M | $-84.52M | $-130.32M | $-191.13M | $-198.94M |
| Investing cash flow | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | $28.14M | $91.65M | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | $10.07M | $34.38M | $122.30M | — | — | — | — |